Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31471091 | 1.00 | PLAU (0.32) | PLAUALDH1A1KMT2A | |
| SCHEMBL20799620 | 0.86 | PLAU (0.33) | PLAUALDH1A1KMT2A | |
| SCHEMBL589119 | 0.83 | ALDH1A1 (0.32) | PLAUALDH1A1KMT2A | |
| SCHEMBL67272 | 0.78 | PLAU (0.43) | PLAU | |
| SCHEMBL10109830 | 0.77 | PLAU (0.33) | PLAU | |
| SCHEMBL31289724 | 0.77 | LMNA (0.39) | ALDH1A1KMT2A | |
| SCHEMBL17427737 | 0.77 | LMNA (0.39) | ALDH1A1KMT2A | |
| SCHEMBL30519316 | 0.76 | — | — | |
| SCHEMBL11834481 | 0.76 | — | — | |
| SCHEMBL11601454 | 0.76 | PLAU (0.37) | PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346767-B2 | Substituted pyrazines and a process for producing the same | JNC CORPORATION (JP) | 2016-05-24 | — | — | US | claimed |
| US-20150266833-A1 | PROCESS FOR PRODUCING v-COELENTERAZINE COMPOUNDS | JNC CORPORATION (JP) | 2015-09-24 | — | — | US | claimed |
| US-20150119575-A1 | PROCESS FOR PRODUCING V-COELENTERAZINE COMPOUNDS | JNC CORP (JP) | 2015-04-30 | — | — | US | claimed |
| US-20140206868-A1 | PROCESS FOR PRODUCING v-COELENTERAZINE COMPOUNDS | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2014-07-24 | — | — | US | claimed |
| US-20120232272-A1 | PROCESS FOR PRODUCING v-COELENTERAZINE COMPOUNDS | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2012-09-13 | — | — | US | claimed |
| EP-4719592-A1 | BICYCLIC COMPOUNDS FOR KETOHEXOKINASE INHIBITION | Centennial Therapeutics, LLC (US) | 2026-04-08 | — | — | EP | disclosed |
| WO-2025072392-A1 | TRIAZOLOPYRIDINYL ETHER LINKED COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2024249612-A1 | BICYCLIC COMPOUNDS FOR KETOHEXOKINASE INHIBITION | CENTENNIAL THERAPEUTICS, LLC (US) | 2024-12-05 | — | — | WO | disclosed |
| EP-4364798-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | Annapurna Bio Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11944622-B2 | Compounds and compositions for treating conditions associated with APJ receptor activity | ANNAPURNA BIO, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| EP-3860998-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | SHOUTI INC. | 2023-06-01 | — | — | US | disclosed |
| US-7662825-B2 | 2,3-Dichloro-N-(3-methoxy-5-methyl-2-pyrazinyl)-benzenesulphonamide; inflammatory diseases, such as asthma | ASTRAZENECA AB (SE) | 2010-02-16 | — | — | US | disclosed |
| EP-1633729-B1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2008-07-30 | — | — | EP | disclosed |
| US-20060122195-A1 | Sulphonamide compounds that modulate chemokine receptor activity (ccr4) | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| EP-1633729-A1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | disclosed |
| US-20060025423-A1 | N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases | ASTRAZENECA AB (SE) | 2006-02-02 | — | — | US | disclosed |
| WO-2004108692-A1 | SULPHONAMIDE COMPOUNDS THAT MODULATE CHEMOKINE RECEPTOR ACTIVITY (CCR4) | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | WO | disclosed |
| EP-1467976-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | AstraZeneca AB (SE) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003059893-A1 | N-PYRAZINYL-PHENYLSULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025423-A1 | N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases | CCL11, CCL2, CCR2 | PLAU 1396/4885ALDH1A1 1544/4885KMT2A 4349/4885 |
| US-20060122195-A1 | Sulphonamide compounds that modulate chemokine receptor activity (ccr4) | CCR4, CCR1, CCR3 | PLAU 3569/4885ALDH1A1 2051/4885KMT2A 3425/4885 |
| US-20140206868-A1 | PROCESS FOR PRODUCING v-COELENTERAZINE COMPOUNDS | F5, METAP2, MTX2 | PLAU 3028/4885ALDH1A1 4782/4885KMT2A 936/4885 |
| US-20120232272-A1 | PROCESS FOR PRODUCING v-COELENTERAZINE COMPOUNDS | F5, METAP2, MTX2 | PLAU 3028/4885ALDH1A1 4782/4885KMT2A 936/4885 |
| US-20150119575-A1 | PROCESS FOR PRODUCING V-COELENTERAZINE COMPOUNDS | F5, VRK2, MTX2 | PLAU 3395/4885ALDH1A1 4780/4885KMT2A 568/4885 |
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | APLNR, AGTR1, AGTR2 | PLAU 662/4885ALDH1A1 2722/4885KMT2A 3033/4885 |
| US-11944622-B2 | Compounds and compositions for treating conditions associated with APJ receptor activity | APLNR, AGTR1, AGTR2 | PLAU 662/4885ALDH1A1 2722/4885KMT2A 3033/4885 |
| US-20150266833-A1 | PROCESS FOR PRODUCING v-COELENTERAZINE COMPOUNDS | F5, VRK2, METAP2 | PLAU 3215/4885ALDH1A1 4766/4885KMT2A 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.